Introduction. Reduction in renal mass in rats results in progressive proteinuria, hypertension, focal-segmental glomerulosclerosis (FSG), atrophy of tubules (AT), and interstitial expansion. We reported that slow reduction of renal tissue in rats (slow ablation) ending in the removal of 1.5 kidneys is associated, over the next six months, with higher albumin excretion rates (AER) and accelerated development of FSG lesions compared to sudden equivalent renal mass reduction. It was hypothesised that slow reduction of nephron numbers allows for a process of conditioning of residual nephrons that increases their susceptibility to subsequent injury. Methods. To test this idea we treated Münich-Wistar rats with the angiotensin receptor blocker (ARB) losartan for six weeks during the gradual staged surgical removal of 1.5 kidneys, and compared them to sham operated controls, and parallel groups untreated by losartan. Results. Despite discontinuation of losartan over the subsequent six months,ARB pre-treatment completely prevented proteinuria and hypertension in these slow renal ablation rats. ARB pre-treatment also largely prevented the subsequent development of FSG,AT, and interstitial expansion in these animals. Both losartan-treated and untreated renal ablation groups had glomerular enlargement and compensatory hyperfiltration and this was uninfluenced by losartan. Conclusion. Temporary ARB administration during gradual renal mass reduction resulted in long-term prevention of hypertension and albuminuria and greatly reduced FSG and tubular and interstitial lesions. We hypothesise that the preconditioning of residual nephrons in the gradual ablation model which facilitates their subsequent injury, is blunted by renin-angiotensin system blockade.
Introduction
The rat remnant kidney model has proven helpful for developing pathogenetic concepts of progressive renal injury, some which have been applied to human research and clinical practice. 1 Reduction of renal tissue in rats over six weeks (slow ablation [SA] ) ending in the removal of 1.5 kidneys was associated, over the next six months, with higher urinary albumin excretion rates (AER) and accelerated development of focal segmental glomerulosclerosis (FSG) lesions compared to sudden equivalent renal mass reduction. 2 These group differences were not due to differences in systemic blood pressure (BP). 2 It was hypothesised that the slow reduction of nephron number allows for a process of conditioning of the residual nephrons which alters their susceptibility to subsequent injury. The present studies were undertaken to test this idea. Given that reninangiotensin system (RAS) blockade can largely prevent the renal physiologic and pathologic consequences of reduction in renal mass, 3, 4 RAS blockade was administered only during the six weeks of SA. This resulted in major alterations in the SA models over the subsequent six months.
Materials and methods

Experimental design
Male Münich-Wistar rats (Simonsen Laboratory, Inc. Gilroy, CA, USA) weighing approximately 250 grams at the start of the experiments were randomly allocated into the following four groups: 1: SA group (randomised N=14; surviving N=14). Gradual reduction in renal mass was accomplished, as previously detailed 2 by the surgical removal of the left upper and lower pole, followed three weeks later by removal of the rest of the left kidney, and three weeks later by removal of the upper and lower pole of the right kidney (the final surgical procedure, [FSP] ). This achieved a total removal of 1.5 kidneys. 2: Slow ablation-losartan treated (SA+L) group (randomised N=14; surviving N=11). Gradual reduction in renal mass was performed exactly as in the SA group, but these animals were treated with the angiotensin II receptor blocker (ARB), losartan (Merck, Inc.), 30 mg/kg/day in the drinking water for six weeks, from the time of the initial surgical procedure to the time of the FSP. 3 : Control (C) group (randomised N=8; surviving N=8). At the initial sham operation, the left kidney was exposed and the renal capsule was removed. At the second sham operation, the left kidney was again exposed and scar tissues removed from the renal surface. Three weeks later, the right kidney was exposed and the renal Throughout the study, all animals had free access to water and food. Twenty-four hour water consumption was measured at weekly intervals during the first six weeks of the study and the concentration of losartan in the drinking water was adjusted on the basis of the actual volume of water consumed to ensure that the correct dose of losartan was ingested. Animals were followed for an additional 24 weeks after the FSP and losartan discontinuation with interval and final studies performed as outlined below.
Separate animals randomised into four groups [C (N=7), C+L (N=7), SA (N=11) and SA+L (N=13)] were utilised for measures of body weight, intraarterial mean blood pressure (IA-MBP) and glomerular filtration rate (GFR) and renal structural studies at the time of the FSP (see below). These animals were sacrificed at this time. At all times, standards of care of animals in these studies adhered to the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Renal functional studies BP, haematocrit and 24-hour AER were measured at baseline (-6 weeks), three (-3 weeks) and six weeks (time 0 or the time of the FSP) and +2, +4, +8, +12, +16, +20 and +24 weeks after the FSP. Systolic blood pressure (SBP) was measured in awake and lightly restrained rats by a tail-cuff method as previously described. 2 Three to four measurements for each rat were obtained at each time point during the study and on the day of GFR measurement and the mean of those three to four measurements were used to estimate SBP. IA-MBP was measured as previously described (2) at the FSP and +24 weeks. The tail cuff and IA-MBP measurements were highly correlated (N=98, r=0.8, p<0.0001), confirming our earlier observations. 2 All rats were individually placed in metabolic cages for 24-hour urine collections to measure AER. Urine albumin concentration was measured by the Bradford protein assay method (Bio-Rad Laboratories, Hercules, CA, USA) using a Spectrophotometer DU Series 600 instrument. GFR was estimated at the FSP and 24 weeks after the FSP in anaesthetised rats using 125 I Iothalamate as a GFR marker as detailed elsewhere. 2
Morphologic and morphometric studies
Renal tissues at sacrifice were bivalved, cut into slices parallel to the longitudinal renal axis, fixed in Zenker's solution and embedded in paraffin. Slices were sectioned at 5 μm, stained with periodic acid-Schiff (PAS), and projected using a special projection microscope onto a 9 x 9 cm grid for estimation of mean glomerular volume (MGV), frequency of glomeruli with focal segmental glomerulosclerosis lesions (%FSG), and severity score of focal segmental glomerulosclerosis lesions (FSG severity score). The reader was masked for all tissue studies.
MGV was measured on at least 60 randomly selected glomerular profiles (see below) at x150 using the point-counting method of Weibel and Gomez. 5, 6 %FSG and FSG severity score were also determined in at least 60 randomly selected glomerular profiles (median=95, range; 64-142) in 30-50 fields at 300x. FSG was recognised as an increase in tuft PAS-positive extracelluar matrix material associated with capillary wall wrinkling and collapse. These FSG lesions were usually, but not always, associated with adhesions to Bowman's capsule. Hyalinosis, characterised by the presence of glomerular tuft PAS-positive ground glass material, was often included in the FSG lesions. 7 The FSG score in a given tissue specimen was assessed by assigning a value of 0 to 4+ to each glomerulus according to the proportion of the tuft occupied by FSG lesions: normal glomerulus, 0; up to 25%, 1+; 25-50%, 2+; 50-75%, 3+; and more than 75%, 4+. The FSG severity score was estimated as the product of the sum of FSG scores and the fraction of glomeruli with FSG. 7 The volume fraction of renal cortex which is interstitium [Vv (Int/cortex)] was estimated by point counting, as previously described. 2, 8 This estimate was performed by point counting on 42.0±6.2, 200x fields per specimen. These fields were acquired for study by systematic unbiased microscope stage movements. Interstitium was defined as that space not occupied by glomeruli, tubules, or vessels larger than one tubular diameter. 8 The volume fraction of cortex occupied by atrophic tubules [Vv (AT/cortex)] was estimated by point counting on the same fields used for Vv (Int/cortex). Atrophic tubules were defined by the presence of thickened or reduplicated tubular basement membranes (TBMs) surrounding tubules of reduced diameters, containing shortened or flat tubular epithelial cells; in the absence of obviously thickened TBMs, atrophy was defined as a tubular diameter reduced to less than 50% of normal, as determined by comparison with adjacent tubules.
Statistics
Data are provided as x ± SD. After testing for normality, analysis of variance or Kruskal-Walis test was chosen for testing for group differences. Post-hoc differences between groups were determined by the least significant difference test. We used mixed model analysis in order to test the group effect, time trend, and the interaction between group effect and time trend of SBP and AER. When the interaction was not significant, we assumed the time trends in each group were parallel and tested for the main effects only. Statistical significance was accepted when the probability of error (p) was <0.05.
Results
Animal data at the time of the FSP Body weight and haematocrit values were similar at study baseline (-6 weeks) in all study groups (data not shown). These variables were also similar in all groups at the time of the FSP (table 1) . The weights of the right kidneys at the FSP were about 30% higher in the slow ablation (SA and SA+L) than in the control (C and C+L) groups (table 1) . The GFRs at the FSP were 1 / 3 lower in the SA and SA+L than in the C and C+L groups (table 1) . There were no statistically significant effects of losartan treatment on any of the above variables in the SA (SA vs. SA+L) or control (C vs. C+L) groups (table 1) . IA-MBP was lower in the losartan treated versus untreated groups, but was not statistically significantly different between the respective control or SA conditions (table 1) .
The course of blood pressure and albumin excretion rate
Blood pressure There were no statistically significant group differences in baseline awake tail-cuff SBP (-6 weeks from the FSP; figure 1 ). There was a decrease in SBP in all losartan treated animal groups (C+L and SA+L) at three and six weeks of losartan administration (p values all <0.001), but there were no differences between the two losartan treated groups (figure 1).
There was a trend towards a time-dependent increase in SBP in C group from 0 to +24th weeks after the FSP (p=0.0505, figure 1 ) and a gradual increase in SBP in the other groups (p=<0.05 for each, figure 1 ). Two weeks after the FSP and losartan cessation the SA+L group had lower SBP than the SA or C groups (p<0.001 for both comparisons; figure 1 ). Subsequently there were no statistically significant SBP differences between these three groups. However, from the +8th to the +24th week the SA group had higher SBP than the C, CL and SA+L groups (p<0.001 for each comparison; figure 1 ). The rate of increase in SBP was greater in the SA than in the C group (p=0.0035) (figure 1). Key: * = p<0.001 C and C+L groups vs. SA and SA+L groups; ** = p<0.001 C and SA groups vs. C+L and SA+L groups; IA-MBP = intra-arterial mean blood pressure; GFR = glomerular filtration rate; C = control; C+L = control-losartan treated; SA = slow ablation; SA+L = slow ablation-losartan treated; ANOVA = analysis of variance. 
Urinary albumin excretion rate
Increased AER was noted in the SA group three weeks after first removal of half a kidney (-3 weeks time point) compared to the C, C+L and SA+L groups and these differences increased with time throughout the remainder of these studies ( figure 2) . AER in the C, C+L and SA+L groups were nearly identical through the study (figure 2). The SA+L group showed a similar age related rate of increase in AER as did the C group (p=0.978 for this comparison) while the rate of increase was significantly greater in the SA group than in C and SA+L groups (both p<0.0001, figure 2 ).
Animal data 24 weeks after the FSP There were no statistically significant group differences in body weight at the end of the studies (table 2) . Total kidney weights in the control groups (C and C+L) exceeded those in the ablated groups (SA and SA+L) by approximately 45% (p<0.001 for each comparison; table 2) but there were no statistical differences in this parameter between the SA and SA+L groups (table 2) . Haematocrit values at sacrifice were slightly but statistically significantly lower in the ablated groups (SA and SA+L) than in C. The GFR's at 24 weeks after the FSP were 45-50% lower in the ablated (SA and SA+L) than in either control groups (C and C+L). The final GFR's in the untreated-ablated and treated-ablated groups (SA vs. SA+L) did not statistically differ (table 2) . The GFR's in the C and CL groups were similar.
Renal structural data at and 24 weeks after the FSP MGV at the FSP was not statistically significantly different in the SA, SA+L, C and C+L animals (table 3) . MGV at 24 weeks after the FSP was increased by 45% or more in the ablated groups (SA and SA+L) compared to the control groups (C and C+L, all p values <0.001, figure 3 ). There was no statistically significant difference in MGV among the ablated groups or among the two control groups.
There were essentially no FSG lesions in the sham operated (C) rats or the SA rats at the FSP (table 3) . FSG frequency and FSG severity score were very low and not statistically different among the C and C+L groups at 24 weeks after the FSP (figures 4 and 5). The median and range for the FSG frequency values were C, 0 (0-3.9%) and C+L, 0 (0-3.7%). Glomeruli with FSG were common in the SA group. There were no discernable qualitative differences in the Paper Table 2 Renal functional parameters at 24 weeks after the final surgical procedures. Key: * = p<0.001 C and C+L groups vs. SA and SA+L groups; ** = p<0.001 C group vs. SA and SA+L groups;*** = p<0.001 C, C+L, and SA+L groups vs. SA group; IA-MBP = intra-arterial mean blood pressure; GFR = glomerular filtration rate; C=control; C+L = control-losartan treated; SA = slow ablation; SA+L = slow ablation-losartan treated; ANOVA = analysis of variance. figure 6 ). However, the SA groups had more than 40-fold increases in FSG frequency and more than 400-fold increases in FSG severity scores compared to the C and C+L groups at 24 weeks (figures 4 and 5). The SA+L group had an average 73% reduction in FSG frequency and 91% reduction in FSG severity score at 24 weeks compared to the untreated SA animals (p<0.001 for each comparison, figures 4 and 5). The SA+L group still had increased %FSG compared to the C and C+L groups (p=0.042 for all comparisons). The FSG severity scores of the SA+L group, however, was not statistically different from that of C or C+L groups (p=0.627 and 0.634, respectively). There were no statistically significant correlations between MGV and either FSG frequency or severity score at 24 weeks after the FSP (data not shown). Paper Table 3 Renal structural data at final surgical procedure. . Vv(Int/cortex) in the SA+L animals was lower than in the SA animals (p=0.036) and did not differ significantly from the C or C+L rats ( figure 7) .
Group
Group Mean glomerular volume Frequency (%) of FSG
The volume fraction of atrophic tubules [Vv(AT/cortex)] was less than 0.5% and not statistically different in the C and C+L animals at 24 weeks. This parameter was more than 5-fold higher in SA animals than the C or C+L rats (figure 8). Vv(AT/cortex) in the SA+L animals was not statistically significantly different from the control group, although there was a trend in this direction (p=0.064). Vv(AT/cortex) in the SA+L group was lower than in the SA group (p=0.033).
Discussion
The model of surgical subtotal nephrectomy was used here and in our previous study (2) in lieu of nephrectomy and contralateral partial renal infarction, since the latter model regularly results in the rapid development of severe hypertension 9 which accelerates the pace of the renal injury, leading to uraemia and death over a relatively short time period. Based on previous experience it was predicted that the SA process would not be associated with a discernable increase in FSG lesions at the FSP in the SA rats. 2 This, indeed, was the case, excluding the possibility that FSG lesions at the FSP could affect the 24 weeks' results.
Inherent in the design of the present studies, the residual nephrons in SA+L rats were exposed to losartan immediately after renal mass reduction had begun. Six weeks of RAS blockade with an ARB, losartan, completely prevented the development of hypertension and albuminuria over the next six months in the slow ablation group. Losartan administration during the six weeks of the phased removal of a single kidney was also associated with marked reduction in the FSG lesions which resulted from the slow removal of 1.5 kidneys. Losartan treatment also reduced interstitial and tubular injury in the slow ablation animals.
As reviewed elsewhere, 10 many studies have demonstrated an association between FGS induced by renal ablation and glomerular haemodynamic abnormalities. Renal ablation in rats causes increased single nephron glomerular capillary pressures and blood flows and manoeuvres such as RAS blockade 3 or reduced dietary protein intake initiated at the time of renal mass reduction, 11 or when the resultant early renal injury was already established, 12 reduced these glomerular haemodynamic consequences and the associated renal structural damage. Low protein diets have this protective effect despite little or no influence on systemic BP measured by the tail cuff method in conscious rats, or intraarterially in anaesthetised rats. 12 Reduction in systemic BP without reduction in glomerular capillary pressure was less protective of glomerular injury. 13 Together, these studies fit with the idea that glomerular capillary hypertension could be an important pathogenetic variable. Measurements of glomerular haemodynamic variables will be necessary to fully understand the present models.
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The argument has been made that glomerular capillary hypertension, alone, may be insufficient to initiate FSG lesions in the renal ablation model in rats in the absence of increases in glomerular volume. 14 Thus, salt restriction in remnant kidney rats reduces glomerular enlargement and glomerular injury and proteinuria despite persistence of glomerular capillary hypertension. 15, 16 Contralateral intraperitoneal urinary drainage results in similar elevations in glomerular capillary pressures and flows in the renal remnants as in rats with contralateral nephrectomy. The urine diverted rats, however, had less glomerular enlargement, less proteinuria, and less FSG in the remnant kidney. 17 Glomerular volume, in the present study, was unchanged at the FSP and equivalently increased 24 weeks after completion of renal mass reduction whether or not the rats received losartan pretreatment. Thus, suppression of glomerular hypertrophy by losartan cannot be invoked as the explanation for the marked reduction in proteinuria and renal lesions in the SA+L animals.
The control animals treated with losartan (C+L) had lower BP during L treatment, but shortly thereafter BP returned to the values of the C rats and, over the course of the next six months, the C+L animals had the same age related increases in tail cuff SBP and IA-MBP, AER, glomerular volume, kidney weight and GFR as did the C rats. Losartan thus did not seem to have prolonged influences on these parameters in the sham operated but otherwise normal animals. The long-term effects of six weeks of RAS blockade with L were restricted to the ablation model. These effects lasted far beyond any recognised persistence of this drug in body tissues or fluids. 18 It is proposed that this long-lasting protection from proteinuria and hypertension represents persistent alterations in tissue cellular behaviours and responses which have sustained influences on the residual nephrons in the ablated animals.
A parallel phenomenon of brief losartan treatment having prolonged effects has been described in spontaneously hypertensive rats (SHR) 19 and in diabetic rats. 20 SHR treated with losartan only from ages three to eight weeks, i.e., before hypertension was established, were protected from hypertension over the subsequent four months. This was associated with reduced pre-glomerular vascular resistance and a pressure-GFR curve which was shifted to the left five to seven weeks after losartan was discontinued. 19 A more recent study demonstrated that seven weeks of treatment of pre-type 2 diabetic OLETF rats with RAS blockade, which was terminated before diabetes onset, was expected reduced proteinuria and subjective estimates of mesangial expansion after 39 weeks of follow-up, despite having no influence on the development of obesity, diabetes, or diabetes related glomerular enlargement in these rats. 20 Unlike the present study, this temporary RAS blockade, with an ARB, an angiotensin-converting enzyme inhibitor, or both, did not prevent the subsequent development of hypertension and only partially suppressed the emergence of proteinuria in the diabetic animals. Interestingly, at 50 weeks of age, and 39 weeks after RAS blockade was discontinued, treated OLETF diabetic rats had lower renal cortical mRNA expression levels for types I and IV collagen, transforming growth factor-beta, and connective tissue growth factor and less collagen content than untreated or hydralazine treated OLETF rats. On the other hand, there were no lasting effects of RAS blockade on renal cortical mRNA expression levels for angiotensin or renin. 20 These along with the present studies, suggest that temporary RAS blockade may have long-lasting influence on renal cellular behaviours.
Conclusions
Temporary ARB administration during gradual renal mass reduction resulted in long-term prevention of hypertension and albuminuria and greatly reduced FSG and tubular and interstitial lesions. We hypothesise that the preconditioning of residual nephrons in the gradual ablation model is blunted by RAS blockade. Further explorations of these phenomena in the slow ablation model of renal injury may provide new paradigms for understanding processes of renal injury and drug action that could have relevance to the primary prevention of human renal diseases. 
